This run could be short-lived.

Intellia TherapeuticsNTLA stock shot higher Tuesday after the Food and Drug Administration said it would allow the company to restart a study of its gene-editing drug in patients with polyneuropathy.

Intellia Therapeutics Inc. (NASDAQ: NTLA) shares are up on Monday following the FDA’s decision to lift the clinical hold on its MAGNITUDE Phase 3 clinical trial. The FDA imposed clinical holds on the ...

Cathie Wood, the CEO of Ark Invest, is known for investing in companies with strong innovative potential. That includes biotechs that specialize in gene editing, a group of techniques that could ...

Intellia Therapeutics (NASDAQ:NTLA) is preparing to release its quarterly earnings on Thursday, 2026-02-26. Here's a brief overview of what investors should keep in mind before the announcement.

The last time I wrote about Intellia Therapeutics (NTLA) it was with respect to a Seeking Alpha article entitled "Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity".

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at JMP Securities in a research note issued on Friday,Benzinga reports. NTLA has been ...

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

Intellia Therapeutics NTLA has put up a stellar performance in the past month. Shares of the company have rallied 29.8% compared with the industry’s rise of 0.4%. The stock has also outperformed the ...